The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Musk revealed using Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, highlighting their popularity for weight management.
The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly’s (LLY.N) blockbuster ...
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...
The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others ...
Eli Lilly and Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means ...
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to ...
The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...
Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...